Home/Pipeline/HIF-1/HIF-2 Targeted Therapy

HIF-1/HIF-2 Targeted Therapy

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Matrix Biomed

About Matrix Biomed

Matrix Biomed is a private, pre-revenue biotech company leveraging a proprietary gene network analysis platform to discover and develop gene-based therapeutics. Its core strategy involves mapping gene regulatory networks to identify and revert abnormal gene expression patterns in diseases, with an initial pipeline aimed at oncology supportive care and direct cancer treatment. The company appears to be in a pre-clinical or early clinical stage, with a website last updated in 2018, indicating potential dormancy or a very early-stage operational status.

View full company profile

Therapeutic Areas

Oncology Rare Genetic Diseases

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active